Dr. Abraham Morgentaler

I can't think of any condition where that's a problem. You know where it comes up is there's still some debate about venothrombotic events, DVTs, pulmonary emboli, things like that. I think the data are clear. I've been involved in a couple of studies around this, and the Traverse Trial 2 showed nothing with that. But I'll tell you how people think and what they do.

I can't think of any condition where that's a problem. You know where it comes up is there's still some debate about venothrombotic events, DVTs, pulmonary emboli, things like that. I think the data are clear. I've been involved in a couple of studies around this, and the Traverse Trial 2 showed nothing with that. But I'll tell you how people think and what they do.

There was a guy, there's a doctor who has published on testosterone and this venous thrombosis risk. He's published a lot on it. And he believes testosterone increases that risk. So there's a epidemiology-type guy who invited me to participate in research that he was doing looking at this problem, and he invited that other doctor who thinks that it's a problem to be an author on the paper.

There was a guy, there's a doctor who has published on testosterone and this venous thrombosis risk. He's published a lot on it. And he believes testosterone increases that risk. So there's a epidemiology-type guy who invited me to participate in research that he was doing looking at this problem, and he invited that other doctor who thinks that it's a problem to be an author on the paper.

The study comes out, or the data comes out, and we're all just discussing it. It's written up, and it doesn't show any increased risk, none. And this guy's a very, his name's Jacques Bayargeon. He's a very accomplished sort of public health researcher. And the fellow who thinks that it's a problem looks at the data and says, well, you didn't look at this and that.

The study comes out, or the data comes out, and we're all just discussing it. It's written up, and it doesn't show any increased risk, none. And this guy's a very, his name's Jacques Bayargeon. He's a very accomplished sort of public health researcher. And the fellow who thinks that it's a problem looks at the data and says, well, you didn't look at this and that.

I think if you do, we're going to find more of these events. So Jacques goes back and he re-looks at the data the way this guy wanted him to and nothing. at which point there's an interesting conversation with the other author and says, listen, if you don't want to be an author on this, I'll understand it, but these are the data we have.

I think if you do, we're going to find more of these events. So Jacques goes back and he re-looks at the data the way this guy wanted him to and nothing. at which point there's an interesting conversation with the other author and says, listen, if you don't want to be an author on this, I'll understand it, but these are the data we have.

And to that fellow's credit, he said, well, listen, you did the analysis, and if that's what it is, I'm happy to be a part of it, which is really the way medicine and science should work. So a credit to him. But where his original work came from is he took people who already were at risk for having DVTs and PEs. Like you can have clotting problems, right?

And to that fellow's credit, he said, well, listen, you did the analysis, and if that's what it is, I'm happy to be a part of it, which is really the way medicine and science should work. So a credit to him. But where his original work came from is he took people who already were at risk for having DVTs and PEs. Like you can have clotting problems, right?

Exactly. So some have the slide in five factor that predisposes to it. And so some people say, well, maybe you shouldn't give testosterone to those people. But this is not clear thinking. So people who are at risk for something are at risk for something.

Exactly. So some have the slide in five factor that predisposes to it. And so some people say, well, maybe you shouldn't give testosterone to those people. But this is not clear thinking. So people who are at risk for something are at risk for something.

If you then add in something like testosterone, which has not been shown to anything, yes, they can get clots again, but it's not because of testosterone. It's because they were at risk for it, right? You might as well say- You just stick a margarine. Let's see if that happens. Exactly. Exactly right. Yeah.

If you then add in something like testosterone, which has not been shown to anything, yes, they can get clots again, but it's not because of testosterone. It's because they were at risk for it, right? You might as well say- You just stick a margarine. Let's see if that happens. Exactly. Exactly right. Yeah.

So the answer is, listen, the big ticket items that we've worried about, prostate cancer, cardiovascular risk, Those are now clean as far as I'm concerned. There's just no data to show that there's a problem.

So the answer is, listen, the big ticket items that we've worried about, prostate cancer, cardiovascular risk, Those are now clean as far as I'm concerned. There's just no data to show that there's a problem.

Oh, yeah.

Oh, yeah.

Yeah, it's an amazing story. So, I started publishing data showing that this old relationship we thought existed between testosterone and prostate cancer wasn't true. And even published in the New England Journal of Medicine.

Yeah, it's an amazing story. So, I started publishing data showing that this old relationship we thought existed between testosterone and prostate cancer wasn't true. And even published in the New England Journal of Medicine.